Dr Nikolai Dyrberg (University of Copenhagen, Denmark) presented the findings of a Danish nationwide study that followed 1,684 patients with psoriasis receiving biologic therapy for the first time [1]. Median response time was 112 days. At baseline, 746 participants had a PASI of 0; 485 had a PASI between 0 and ≤2; 246 had a PASI >2 but ≤4; and 207 had a PASI >4. Defining a flare-up as any increase of their PASI score by ≥3, 42.8% of patients experienced flare-ups. However, patients with a lower PASI score during the first 6 months of treatment experienced longer flare-free periods. These outcomes were independent of drug, sex, age, weight, and use of methotrexate.
Dr Dyrberg’s team documented a more stable disease course, lower risk of flares, and decreased treatment discontinuation in bio-naïve patients with psoriasis treated with biologics who had a low early PASI response. Given these results, they recommend a treatment target of PASI ≤2 in the first year of treatment in this patient group.
- Dyrberg Loft N. Risk of disease flares during first biologic therapy among patients with stable and controlled psoriasis: A Danish Nationwide Study. P1331, EADV Virtual Congres, 29-31 October 2020.
Posted on
Previous Article
« Discontinuation of omalizumab during COVID-19 pandemic associated with poor outcomes for chronic spontaneous urticaria Next Article
Oral prevention of skin cancer »
« Discontinuation of omalizumab during COVID-19 pandemic associated with poor outcomes for chronic spontaneous urticaria Next Article
Oral prevention of skin cancer »
Related Articles
October 30, 2020
JAK1 inhibition successful in hidradenitis suppurativa
November 13, 2023
Comorbidity in adult psoriasis
November 19, 2023
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com